5LBA Everolimus in advanced nonfunctional neuroendocrine tumors (NET) of lung or gastrointestinal (GI) origin: Efficacy and safety results from the placebo-controlled, double-blind, multicenter, Phase 3 RADIANT-4 study. (September 2015)

• Record Type: Journal Article
• Authors: Yao, J.; Fazio, N.; Singh, S.; Buzzoni, R.; Carnaghi, C.; Wolin, E.; Tomasek, J.; Raderer, M.; Lahner, H.; Voi, M.; Pacaud, L.; Lincy, J.; Sachs, C.; Valle, J.; Delle Fave, G.; Van Cutsem, E.; Tesselaar, M.E.T.; Shimada, Y.; Oh, D.Y.; Strosberg, J.; Kulke, M.H.; Pavel, M.E.
• Is Part Of: European journal of cancer. Volume 51:(2015)Supplement 3
• Page Start: S709
• Page End: S710
• Publication Date: 2015-09
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(16)31928-1
• Languages: English
• ISSNs: 0959-8049